Log in to search using one of your social media accounts:

 

Amedica plans 510(k) submission for new cervical implant in Oct, touts Q1, Q2 prelim earnings
Amedica (NSDQ:AMDA) said today that after a 510(k) pre-submission meeting with the FDA, it is on track to submit a 510(k) application for a modified porous cervical implant next month, and announced preliminary earnings for its 1st and 2nd quarters. The company said it is entering the beta launch of its Taurus pedicle screw system which won FDA clearance last November, looking to release additional sets of the device during the 4th quarter as it looks to increase access to the devices. For its 1st quarter, the Salt Lake City, Utah.-based company said it expects to report revenue of $2.6 million, with net loss per shar...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Regulatory/Compliance Spinal Amedica Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 22, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. 5 DeviceTalks Boston exhibitors you should know DeviceTalks Boston is an annual event that allows some of the best minds in medtech to exchange ideas, insights and technologies. The event is hosted by MassDevice. Those who atte...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: MassDevice Tags: Blog Plus 5 Source Type: news

Arianna Huffington: 10 Ways to Actually, Finally Improve Company Culture
There are endless truisms about the importance of company culture — so many that the idea of a strong culture has become a cliché. We often just nod our heads and move on. But it matters. So how can we put flesh and blood on the idea to make it more than just a nice saying? How can companies embody the connection between culture and the bottom line? Here are ten ways. 1) End the burnout delusion. Burnout is not the price we must pay for success. Leaders need to realize that taking care of their human capital is just as important as PnL, Ebitda and quarterly earnings. Living a sustainable life, and making sure ...
Source: TIME.com: Top Science and Health Stories - September 21, 2017 Category: Consumer Health News Authors: Arianna Huffington Tags: Uncategorized Careers & Workplace The CEO Initiative Source Type: news

NuVasive shares slide on negative note from analyst
UPDATE: Updated to reflect that Cowen & Co. did not downgrade the stock, but issued a negative note. NuVasive Inc. (NSDQ:NUVA) shares dropped over 7% after financial group Cowen & Co. issued a negative note on the company following a report from short seller GlassHouse Research which accused the company of “irregular accounting,” according to a Benzinga report. The short seller’s report claims that the company was using accounting tricks to hide that its organic business is in decline, according to Benzinga, and accuses the company of inflating its earnings and growth numbers. GlassHouse used...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Nuvasive Source Type: news

NuVasive shares slide on negative note short seller report
UPDATE: Removed reference to financial group Cowen & Co. after verification that it did not release any negative sentiments towards NuVasive based on the GlassHouse report. NuVasive Inc. (NSDQ:NUVA) shares dropped over 7% after the release of a report from short seller GlassHouse Research which accused the company of “irregular accounting,” according to a Benzinga report. The short seller’s report claims that the company was using accounting tricks to hide that its organic business is in decline, according to Benzinga, and accuses the company of inflating its earnings and growth numbers. GlassHou...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Nuvasive Source Type: news

K2M launches Everest MI XTower spinal instrumentation
K2M (NSDQ:KTWO) said yesterday it launched its Everest minimally invasive XTower instrumentation designed to work with its Everest MI XT spinal system. The XTower addition allows surgeons to use the Everest MI XT system to treat complex defomities to achieve 3-dimensional spinal balance, the Leesburg, Va.-based company said. “The addition of the Everest MI XTower to the Everest MI XT spinal system provides surgeons with intraoperative customization of screw extension rigidity based on the intended clinical application. The increased screw extension strength provided by the XTower allows surgeons to treat a ...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Spinal K2M Source Type: news

Rafael Nadal Wins the U.S. Open and Brings Superstar Quality Back to Men ’s Tennis
Who called this one? Exactly no one, that’s who. Coming into this year’s tennis season, sports writers and commentators were contemplating career obituaries for Rafael Nadal and Roger Federer, rather than predicting that they would sweep the season’s Grand Slams. Who could blame them for preparing for the end of Roger and Rafa, whose stocks were slipping? Nadal’s 2016 results were a dour read: loses the first round at the Australian Open; withdraws from the French Open — where he had won nine titles — with a wrist injury before the third round; misses Wimbledon due to a bum wrist; fails ...
Source: TIME.com: Top Science and Health Stories - September 11, 2017 Category: Consumer Health News Authors: Sean Gregory Tags: Uncategorized Australian Open French Open Grand Slams Kevin Anderson Rafael Nadal Roger Federer tennis US Open Wimbledon Source Type: news

A Devastating Hurricane Season Exposes America ’s Flood Insurance Problem
As Hurricane Irma continued on a collision course toward South Florida with wind speeds topping 150 mph, millions of people in the region boarded up their homes and packed up their bags. In the face of a storm that is predicted to be devastating, the question looming over many families is whether they will be able to afford to rebuild their homes if they’re destroyed. At the heart of that question is the issue of flood insurance — an increasingly fraught topic not just in South Florida but in the flood-prone regions of the country as a whole. Private insurance companies moved away from offering flood insurance ...
Source: TIME.com: Top Science and Health Stories - September 9, 2017 Category: Consumer Health News Authors: Justin Worland Tags: Uncategorized Congress FEMA hurricane irma Natural Disasters Source Type: news

Bowel cancer warning: Quarter of people are mistaking deadly symptoms for THIS
BOWEL cancer symptoms include bloating and weight loss, but thousands are mistaking them for signs of an issue with their diet. (Source: Daily Express - Health)
Source: Daily Express - Health - September 8, 2017 Category: Consumer Health News Source Type: news

Can Next-Gen Obesity Balloon Pump Confidence in Apollo?
Apollo Endosurgery's Orbera365 weight-loss balloon works the same way as the original Orbera device, except it is designed to stay in the patient's stomach for 12 months, twice as long as the previous version. Apollo Endosurgery said it has received CE Mark approval to sell its Orbera365 weight-loss system in Europe, doubling the amount of time the balloon stays inflated in the patient's stomach. The approval comes less than a month after FDA alerted doctors of patient deaths associated with obesity balloons made by Apollo and ReShape Medical. The news deflated Apollo's stock (NASDAQ: APEN), as shares sold o...
Source: MDDI - September 6, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Apollo Endosurgery wins CE Mark for 12-month Orbera weight loss balloon
Apollo Endosurgery said today it won an expanded CE Mark approval for its Orbera weight loss system, extending the indwell period of the gastric balloon from 6 months to a 12 month treatment period. The balloon device is designed to be inserted non-surgically in obese patients with body mass indexes of 30 to 40, the Austin, Texas-based company said. After insertion, the balloon is inflated to fill space in the stomach. “I’ve been using Orbera since 1999 and have helped thousands of patients lose weight with my Orbera program. Now with Orbera365 patients will have the possibility of getting better weight loss re...
Source: Mass Device - August 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blog Apollo Endosurgery Source Type: news

Southcoast Health says turnaround plan in works after Q3 losses
Southcoast Health says it is undertaking a turnaround plan, after posting its third consecutive quarter of losses. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 27, 2017 Category: American Health Authors: Jessica Bartlett Source Type: news

Southcoast Health says turnaround plan in works after Q3 losses
Southcoast Health says it is undertaking a turnaround plan, after posting its third consecutive quarter of losses. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 27, 2017 Category: Biotechnology Authors: Jessica Bartlett Source Type: news

Lowered admission rates expected for hospitals
(Reuters) – Weak patient admissions that plagued U.S. hospital operators in the June quarter are likely to persist through 2018, as patients fret about soaring out-of-pocket costs and the future of Obamacare remains uncertain. Companies including HCA Healthcare Inc, the largest for-profit hospital operator, and Tenet Healthcare Corp have reported dismal quarterly results and cut their forecasts for the year. High-deductible health plans – which shift initial medical costs to patients, but have lower monthly premiums – are becoming popular, resulting in patients pushing back non-emergency surgeries. Tenet ...
Source: Mass Device - August 23, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Hospital Care Source Type: news

MassDevice.com +5 | The top 5 medtech stories for August 22, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Silver and electricity can kill bacteria: Here’s how Swedish researchers have developed a way to use silver nanoparticles and electrical currents to prevent bacteria from growing on plastic surfaces – helping to pre...
Source: Mass Device - August 22, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic beats profit estimates led by strong heart device sales
(Reuters) - Medical device maker Medtronic Plc on Tuesday reported a quarterly profit that beat analysts' estimates, driven by strong demand for its heart and vascular devices. (Source: Reuters: Health)
Source: Reuters: Health - August 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Medtronic logs fiscal Q1 earnings beat, but sales miss the mark
Medtronic (NYSE:MDT) beat the consensus forecast on Wall Street with its fiscal 2018 first-quarter earnings, but missed the mark when it came to sales. The world’s largest medical device operation today posted profits of $1.02 billion, or 74¢ per share, on sales of $7.39 billion for the three months ended July 28, for a bottom-line gain of 9.4% on sales growth of 3.1% compared with fiscal Q1 2017. Adjusted to exclude one-time items, earnings per share were $1.12, 4¢ ahead of The Street, where analysts were looking for sales of $7.45 billion. MDT shares, which closed up slightly yesterday at $83.52 apiece, t...
Source: Mass Device - August 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news

UPDATE: Medtronic logs fiscal Q1 earnings beat, but sales miss the mark
UPDATED August 22, 2017, with segment results, share price. Medtronic (NYSE:MDT) beat the consensus forecast on Wall Street with its fiscal 2018 first-quarter earnings, but missed the mark when it came to sales. The world’s largest medical device operation today posted profits of $1.02 billion, or 74¢ per share, on sales of $7.39 billion for the three months ended July 28, for a bottom-line gain of 9.4% on sales growth of 3.1% compared with fiscal Q1 2017. Adjusted to exclude one-time items, earnings per share were $1.12, 4¢ ahead of The Street, where analysts were looking for sales of $7.45 billion. MDT sh...
Source: Mass Device - August 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news

MiMedx divests Stable Biologics subsidiary in transition to focus on biopharma
MiMedx (NSDQ:MDXG) said today it inked a definitive agreement with the former shareholders of Stability Inc. to divest itself of Stability Biologics, which it acquired last January. The Marietta, Ga.-based company said the divestiture is part of its plan to transition back into a biopharmaceutical-focused company. “The transaction is expected to be completed in the 3rd quarter of 2017, and the consideration will include a promissory note issued by Stability Biologics in the principal amount of $3.5 million in favor of MiMedx and a waiver by the former stockholders of Stability, Inc. ...
Source: Mass Device - August 18, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Regenerative Medicine MiMedx Group Inc. Stability Biologics Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight Update your membership record today! If you have completed the renewal process before Friday, July 21, you can expect to receive your membership certificate by the end of August. If you have not yet verified that your organization’s record is up-to-date, check out our Membership renewal flyer for more information. A solar eclipse will be visible across North America for 2 to 3 hours on Monday, August 21. This is a rare and exciting opportunity, but should be attempted with caution. Check out the National Eye Institute...
Source: NN/LM Middle Atlantic Region Blog - August 18, 2017 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

Endologix touts data from AFX, AFX 2 aortic stent graft trial
Endologix (NSDQ:ELGX) touted data today from its Leopard clinical trial, which compared Endologix’s AFX and AFX2 endografts to other commercially available bifurcated aortic endografts. The trial, which launched in 2015, has since enrolled 458 patients. The study’s primary endpoint is freedom from aneurysm-related complications, including aneurysm rupture, conversion to open repair and endoleaks. Freedom from ARC with AFX or AFX2 is 84.7%, compared to 82% for patients treated with other devices, based on data from patients who have reached their one-year follow-up. The company said it plans to stop further...
Source: Mass Device - August 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Wall Street Beat Endologix Source Type: news

Kaiser Permanente Hawaii reports net loss of $11.9M for Q2
Kaiser Permanente Hawaii reported a net loss of $11.9 million for the quarter ending June 30, compared to net income of $3.7 million from 2016 ’s comparable period. Operating expenses were $378.6 million for the quarter, resulting in an operating loss of $12.9 million. Last year’s operating expenses for the quarter were $337.9 million, resulting in operating income of $2.6 million. The state's largest health maintenance organization said membership was 251,010 as of June 30, an increase of… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 16, 2017 Category: Health Management Authors: Anna Hrushka Source Type: news

Kaiser Permanente Hawaii reports net loss of $11.9M for Q2
Kaiser Permanente Hawaii reported a net loss of $11.9 million for the quarter ending June 30, compared to net income of $3.7 million from 2016 ’s comparable period. Operating expenses were $378.6 million for the quarter, resulting in an operating loss of $12.9 million. Last year’s operating expenses for the quarter were $337.9 million, resulting in operating income of $2.6 million. The state's largest health maintenance organization said membership was 251,010 as of June 30, an increase of… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 16, 2017 Category: Biotechnology Authors: Anna Hrushka Source Type: news

Milestone Scientific logs Q2 beat
Injection device maker Milestone Scientific (NYSE:MLSS) topped expectations on Wall Street today with its second quarter results. The Livingston, N.J.-based company posted a net loss of -$1.5 million on sales of $2.5 million for the 3 months ended June 30, for bottom-line growth of 6.8% on sales growth of 4.2% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Milestone Scientific logs Q2 beat appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat milestonescientific Source Type: news

Evolent Health raises $167m
Evolent Health (NYSE:EVH) said yesterday that it raised nearly $167 million in a secondary offering, saying it could use some of the proceeds on the M&A trail. The Arlington, Va.-based value-based healthcare company said it sold more than 8.8 million shares at $19.85 apiece, for net proceeds of roughly $166.8 million. “Evolent Health expects to use such net proceeds for working capital and other general corporate purposes, including to expand its business through acquisitions and investments,” the company said in a regulatory filing. The closure of the offering yesterday started the clock on a 30-day u...
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Wall Street Beat Evolent Health valuebasedhealthcare Source Type: news

Pavmed beats Q2 EPS by a penny
Medical device maker Pavmed Inc. (NSDQ:PAVM) topped expectations on Wall Street with its second quarter results today. The New York-based company posted a net loss of -$989,707, or -8¢ per share, for the 3 months ended June 30, for bottom-line growth of 25% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Pavmed beats Q2 EPS by a penny appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Vascular Wall Street Beat Pavmed Source Type: news

Denver dental group loses money, dentists in Q2
Denver-based Birner Dental Management Services Inc., parent of Perfect Teeth dental practices, reported a net loss of income and a net loss of dentists in its network in the latest quarter. Birner Dental (OTC bulletin board: BDMS) reported a second-quarter loss of $901,000, or a loss of 48 cents per share, compared with a net loss of $230,000, or a loss of 12 cents a share a year earlier. Revenues fell to $14.8 million from $15.8 million a year earlier. Company officials blamed the loss of dentists… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 14, 2017 Category: American Health Authors: Ben Miller Source Type: news

Dentsply Sirona shares steady despite Q2 sales miss
Shares in Dentsply Sirona (NSDQ:XRAY) have fallen slightly today after the medical device maker met earnings per share expectations but missed sales consensus on Wall Street with its 2nd quarter earnings report. The York, Penn.-based company posted losses of $1.1 billion, or $4.58 per share on sales of $992.7 million for the 3 months ended June 30, seeing a massive 1096% swing from profits to losses while sales shrunk 2.9% compared with the same period during the previous year. Adjusted to exclude 1-time items, earnings per share were 65¢, just in line with the 65¢ consensus on Wall Street, where a...
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Dentsply Sirona Source Type: news

SteadyMed tops Q2 sales, EPS estimates
Shares in SteadyMed (NSDQ:STDY) fell today after the pharmaceutical company beat sales expectations on Wall Street with its second quarter results, but missed EPS estimates. The San Ramon, Calif.-based company posted a net loss of -$8.1 million on sales of $319,000 for the 3 months ended June 30, for bottom-line loss of -14% on sales growth of 239.4% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post SteadyMed tops Q2 sales, EPS estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Drug-Device Combinations Food & Drug Administration (FDA) MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat SteadyMed Therapeutics Source Type: news

Cytori Therapeutics posts mixed Q2
Shares in Cytori Therapeutics (NSDQ:CYTX) fell today after the biotech missed sales expectations on Wall Street with its second quarter results, but topped EPS estimates. The San Diego, Calif.-based company posted a net loss of -$6 million on sales of $1.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales loss of -47% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Cytori Therapeutics posts mixed Q2 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Regenerative Medicine Wall Street Beat Cytori Therapeutics Source Type: news

Viveve inks distro deal with InControl Medical, posts Q2 miss
Shares in Viveve (NSDQ:VIVE) have stayed steady today after the company announced a new exclusive distribution deal with InControl Medical and released 2nd quarter earnings that missed expectations on Wall Street. Under the agreement, Englewood, Colo.-based Viveve said it will be granted exclusive rights to distribute all of InControl Medical’s products to healthcare providers in the US. “We are pleased with the opportunity to partner with Viveve to enable wider distribution of our clinically proven devices to U.S. medical professionals who can help the millions of patients suffering from pelvic floor and ...
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution MassDevice Earnings Roundup Wall Street Beat Viveve Medical Source Type: news

IntelGenx misses Q2 sales, earnings estimates
Drug delivery company IntelGenx (CVE:IGX) missed expectations on Wall Street yesterday with its second quarter results. The Quebec-based company posted a net loss of -$550,000 on sales of $1.1 million for the 3 months ended June 30, paring its losses by 32% on sales growth of 64% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post IntelGenx misses Q2 sales, earnings estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat IntelGenx Source Type: news

Cyanotech Corp. reports net income of $501,000 for Q1 2018
Cyanotech Corp., a Hawaii-based nutrition and health products company, reported net income of $501,000, or 9 cents per diluted share, for the quarter ending June 30, compared to a net loss of $691,000, or 12 cents per diluted share, from 2016 ’s comparable period. The Kailua-Kona company reported net sales of $8.8 million for the first quarter of fiscal year 2018, an increase of 20.3 percent compared to the first quarter of fiscal 2017, where net sales were $7.3 million. The company reported gross… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 11, 2017 Category: Biotechnology Authors: Anna Hrushka Source Type: news

Navigating South Korea ’s Healthcare Paradox
In recent years, we have witnessed an explosion of interest among our pharmaceutical clients in conducting research in South Korea. Some emerging market analysts have suggested a ‘K’ should be added to BRIC, reflecting the country’s burgeoning economic status and its increasingly inclusion in global studies, not just regional Asia Pacific or emerging market studies. Indeed, there is ongoing debate about whether South Korea can still be considered ‘emerging’ as it i s a growing player in the pharmaceutical industry in its own right.   As well as looking at South Korea ’s health...
Source: EyeForPharma - August 11, 2017 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

Cyanotech Corp. reports net income of $501,000 for Q1 2018
Cyanotech Corp., a Hawaii-based nutrition and health products company, reported net income of $501,000, or 9 cents per diluted share, for the quarter ending June 30, compared to a net loss of $691,000, or 12 cents per diluted share, from 2016 ’s comparable period. The Kailua-Kona company reported net sales of $8.8 million for the first quarter of fiscal year 2018, an increase of 20.3 percent compared to the first quarter of fiscal 2017, where net sales were $7.3 million. The company reported gross… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 11, 2017 Category: American Health Authors: Anna Hrushka Source Type: news

Titan Pharmaceuticals misses estimates in Q2
Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The San Francisco, Calif.-based company posted a net loss of -$3.5 million on sales of $77,000 for the 3 months ended June 30. In the same period last year, Titan posted profits of $11.9 million on sales of $15 million, thanks to a one-time milestone payment following FDA approval of its buprenorphine implant, Probuphine. Get the full story at our sister site, Drug Delivery Business News. The post Titan Pharmaceuticals misses estimates in Q2 appeared ...
Source: Mass Device - August 10, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Implants MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Titan Pharmaceuticals Source Type: news

BioDelivery Sciences beats Q2 rev estimates, misses on EPS
Shares in BioDelivery Sciences International (NSDQ:BDSI) fell today after the pharmaceutical company beat sales estimates but missed earnings expectations on Wall Street with its second quarter results. The Raleigh, N.C.-based company posted a net loss of -$14.9 million on sales of $8.7 million for the 3 months ended June 30, paring losses by 9.7% on sales growth of 75% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post BioDelivery Sciences beats Q2 rev estimates, misses on EPS appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 10, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pain Management Pharmaceuticals Wall Street Beat BioDelivery Sciences International Source Type: news

Titan Medical shares dip on Q2 earnings release
Shares in surgical robotic platform developer Titan Medical (TSX:TMD) fell today after the company released its 2nd quarter earnings results, despite posting lowered research & development costs and more cash on hand. The Toronto-based company said it spent $2.7 million on R&D, down from $7.7 million in the same period the previous year. Net and comprehensive loss for the quarter was $1.9 million, down from $7.9 million the year prior. Titan Medical said its cash on hand as of June 30 was $6.8 million, up from the $4.3 million it reported having on hand as of December 31, 2016. “The 2nd quarter of 2017 w...
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Titan Medical Inc. Source Type: news

Corindus Vascular Robotics shares dip despite Q2 beat
Shares in Corindus Vascular Robotics (NYSE:CVRS) have fallen today despite the surgical robotics developer posting 2nd quarter earnings which topped Wall Street expectations. The Waltham, Mass.-based company posted losses of $8.4 million, or 4¢ per share, on sales of $2.3 million for the 3 months ended June 30, seeing losses grow 10.8% while sales grew a massive 344.5% compared with the same period last year. Losses per share were just ahead of the 5¢ consensus on Wall Street. “Our 2nd quarter results reflect continued commercial progress. We are encouraged by our growing traction with the CorPath GRX ...
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Corindus Vascular Robotics Source Type: news

Inovio tops Q2 sales estimate by $4m
Shares in Inovio Pharmaceuticals (NSDQ:INO) rose today after the pharmaceutical company beat expectations on Wall Street with its second quarter results. The Plymouth Meeting, Penn.-based company posted a net loss of -$9.5 million on sales of $20.4 million for the 3 months ended June 30, for bottom-line growth of 49% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Inovio tops Q2 sales estimate by $4m appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Oncology Pharmaceuticals Wall Street Beat Inovio Pharmaceuticals Source Type: news

Stratasys shares steady on Q2 beat
Shares in Stratasys have fallen slightly today after the 3D printing and additive manufacturing company met expectations on Wall Street with its 2nd quarter earnings results. The Eden Prairie, Minn.-based company posted losses of $6.2 million, or 11¢ per share, on sales of $170 million for the 3 months ended June 30, seeing losses shrink 67% while sales shrunk 1.2% compared with the same period during the prior year. Read the whole story on our sister site, Medical Design & Outsourcing The post Stratasys shares steady on Q2 beat appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat stratasys Source Type: news

Avinger shares slide on Q2 miss
Shares in Avinger (NSDQ:AVGR) fell today after the medical device developer missed expectations on Wall Street with its 2nd quarter earnings results. The Redwood City, Calif.-based company posted losses of $12.8 million, or 54¢ per share, on sales of $2.5 million for the 3 months ended June 30, seeing losses shrink 5.2% while sales shrunk 47.5% compared with the same period last year. Read the whole story on our Sister Site, Medical Design & Outsourcing The post Avinger shares slide on Q2 miss appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Avinger Source Type: news

Clearside Biomedical misses EPS estimate in Q2
Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the biopharmaceutical company missed earnings expectations on Wall Street with its second quarter results. The Alpharetta, Ga.-based company posted a net loss of -$13.8 million on sales of $130,000 for the 3 months ended June 30, for bottom-line loss of -169% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical misses EPS estimate in Q2 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news

LivaNova shares rise on Q2 beat
Shares in LivaNova (NSDQ:LIVN) rose today after the medical device maker beat expectations on Wall Street with its 2nd quarter earnings results. The London-based company posted profits of $47.5 million, or 98¢ per share, on sales of $321.4 million for the 3 months ended June 30, seeing massive bottom-line growth of 427.8% while sales grew a smaller 0.1% compared with the same period last year. Adjusted to exclude 1-time items, earnings per share were $1.01, well ahead of the 82¢ consensus on Wall Street, where analysts were expecting to see sales of $315.6 million, which LivaNova topped. “We made progr...
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat LivaNova Source Type: news

Novo Nordisk shares rise on solid Q2 results
Diabetes drugmaker Novo Nordisk (NYSE:NVO) posted Street-beating second quarter results today, lifting its full-year sales forecast despite lingering concerns relating to U.S. drug pricing pressures. Last year, the Danish company saw shares drop more than 40% after it slashed its long-term operating profit forecasts, citing price pressures in the U.S. market. Today, Novo Nordisk raised its full-year sales growth forecast in local currencies from o% – 3% to 1% – 3%. Get the full story at our sister site, Drug Delivery Business News. The post Novo Nordisk shares rise on solid Q2 results appeared first on Mas...
Source: Mass Device - August 9, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news

MassDevice.com +5 | The top 5 medtech stories for August 8, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Why the medtech contract manufacturing M&A trend isn’t slowing down Consolidation is increasingly shaping the medical device industry, but what about players on the other side of the fence? Medtech contract manufactur...
Source: Mass Device - August 8, 2017 Category: Medical Devices Authors: MassDevice Tags: Blog News Well Plus 5 Source Type: news

Luminex tops Q2 estimates
Shares in Luminex (NSDQ:LMNX) rose today after the company beat expectations on Wall Street with its second quarter results. The Austin, Tx.-based company posted profits of $5.5 million, or 13¢ per share, on sales of $76.5 million for the 3 months ended June 30, for bottom-line growth of -1.9% on sales growth of 19% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Luminex tops Q2 estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diagnostics MassDevice Earnings Roundup Wall Street Beat Luminex Source Type: news

MannKind posts mixed Q2
Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results. The Valencia, Calif.-based company posted a net loss of -$35.4 million on sales of $2.2 million for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of 100% compared with the same period last year. Get the full story at out sister site, Drug Delivery Business News. The post MannKind posts mixed Q2 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Mannkind Corp. Source Type: news

Evolent Health shares tumble on Q2 EPS miss
Shares in Evolent Health (NYSE:EVH) have dropped over 15% today after the value-based healthcare company beat sales expectations but missed earnings per share consensus on Wall Street with its 2nd quarter earnings results. The Washington D.C.-based company posted losses of $16.9 million, or 28¢ per share, on sales of $107.1 million for the 3 months ended June 30, seeing bottom-line losses grow 101.6% while sales grew 89.4% compared with the same period last year. Adjusted to exclude 1-time items, losses per share were 13¢, behind the 8¢ loss per share consensus on The Street, where analysts were looking...
Source: Mass Device - August 8, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Evolent Health Source Type: news